WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100384
CAS#: 92118-27-9
Description: Fotemustine is a chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of guanine, resulting in N1-guanine and N3-cytosine cross linkages, inhibition of DNA synthesis, cell cycle arrest, and finally apoptosis. This agent is lipophilic and crosses the blood-brain barrier. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
MedKoo Cat#: 100384
Name: Fotemustine
CAS#: 92118-27-9
Chemical Formula: C9H19ClN3O5P
Exact Mass: 315.07508
Molecular Weight: 315.69
Elemental Analysis: C, 34.24; H, 6.07; Cl, 11.23; N, 13.31; O, 25.34; P, 9.81
Fotemustine, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.
Synonym: Foreign brand name: Muphoran. Code name: S 10036.
IUPAC/Chemical Name: diethyl (1-(3-(2-chloroethyl)-3-nitrosoureido)ethyl)phosphonate
InChi Key: YAKWPXVTIGTRJH-UHFFFAOYSA-N
InChi Code: InChI=1S/C9H19ClN3O5P/c1-4-17-19(16,18-5-2)8(3)11-9(14)13(12-15)7-6-10/h8H,4-7H2,1-3H3,(H,11,14)
SMILES Code: CC(P(OCC)(OCC)=O)NC(N(CCCl)N=O)=O
The following data is based on the product molecular weight 315.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively). (source: http://en.wikipedia.org/wiki/Fotemustine).
